Furthermore, adaptive hypoxia to anti-VEGF antibody leads to dysfunctional glutamate/cystine antiporter activity in tumor cells, elevating tumor-derived glutamate and subsequently enhancing Treg function [118]. This evidence concerns the gene VEGFA and neoplasm.